Eszopiclone
| Eszopiclone | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 388.80 g/mol [1] |
| Appearance | White to light-yellow crystalline solid [1] |
| Melting point | 202-203 [1] |
| Boiling point | 487.2 [1] |
| Solubility | soluble in water [1] |
| Predicted LogP | 0.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H17ClN6O3 |
| IUPAC name | [(7S)-6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate |
| SMILES | CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl |
| InChI | InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1 |
| InChIKey | GBBSUAFBMRNDJC-INIZCTEOSA-N |
| CAS number | 138729-47-2 |
| UNII | UZX80K71OE |
| PubChem CID | 969472 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 6 hours |
| Metabolism | Liver oxidation and demethylation (CYP3A4 and CYP2E1-mediated) |
| Excretion | Kidney |
| Routes of administration | By mouth |
| Dosing[] |
|---|
| Sublingual [] | |
|---|---|
| Light | ≤ 6.8 mg(6x - 27.3%) |
| Common | 6.8 - 8.8 mg(5x - 22.7%) |
| Strong | 8.8 - 10 mg(7x - 31.8%) |
| Heavy | 10 - 14.7 mg(1x - 4.5%) |
| Extreme | 14.7 mg +(3x - 13.6%) |
| Oral [] | |
|---|---|
| Light | ≤ 13.2 mg(10x - 47.6%) |
| Common | 13.2 - 20 mg(5x - 23.8%) |
| Strong | 20 - 22.5 mg(1x - 4.8%) |
| Heavy | 22.5 - 30 mg(5x - 23.8%) |
| Extreme | 30 mg + |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Eszopiclone (also known as Lunesta, (S)-Zopiclone, Estorra, Esopiclone, (+)-Zopiclone, Eszopiclon, Eszopiclone civ, Sep-190, eszopiclona or Gsk-1755165) is a substance of the cyclopyrrolone class.
Chemistry
Stereochemistry []
Eszopiclone is a single defined stereoisomer (optical activity ( + )).
Druglikeness
Lipinski's rule of five
Eszopiclone matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- hypnotics and sedatives (N05C)
- benzodiazepine related drugs (N05CF)
- eszopiclone (N05CF04)
MeSH Classification
- hypnotics and sedatives (M0010885)
Mechanism of action []
The exact mechanism of action of eszopiclone is unknown at this time but is thought to occur via binding with the GABA receptor complexes at binding sites located near benzodiazepine receptors, possibly explaining its hypnotic and sedative effects. It has particular affinity for GABA-A (or GABAA) receptor subunits 1, 3 and 5. Eszopiclone increases GABA-A channel currents significantly. GABA-A channels are major inhibitory channels that cause CNS depression when their receptors are activated. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | metabolism / inhibition / induction | 216 |
|---|---|---|
| GABRA1 | shared target | 29 |
| GABRA2 | shared target | 27 |
| GABRA3 | shared target | 27 |
| GABRA4 | shared target | 27 |
| GABRA5 | shared target | 27 |
| GABRA6 | shared target | 27 |
| GABRB1 | shared target | 27 |
| GABRB2 | shared target | 27 |
| GABRB3 | shared target | 27 |
| GABRD | shared target | 27 |
| GABRE | shared target | 27 |
| GABRG1 | shared target | 27 |
| GABRG2 | shared target | 27 |
| GABRG3 | shared target | 27 |
| GABRP | shared target | 27 |
| GABRQ | shared target | 27 |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 969472, Eszopiclone. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/969472
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Eszopiclone. UNII: UZX80K71OE. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/UZX80K71OE
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Lunesta- eszopiclone tablet, coated. DailyMed. 24 May 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd047b2b-05a6-4d99-95cb-955f14bf329f
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 18:59:57 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 18:59:53 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 18:59:53 |
| gsrs | ok | 2026-11-20 18:59:53 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014546) | 2026-11-20 18:59:53 |
| kegg | ok | 2026-11-20 18:59:55 |
| pubchem | ok | 2026-11-20 18:59:53 |
| missing (no r/tripreports posts mention it) | 2026-11-20 18:59:53 | |
| sider | missing (not in SIDER) | 2026-11-20 18:59:53 |
| structure | ok | 2026-11-20 18:59:53 |
| wikipedia | ok | 2026-11-20 18:59:53 |